Candriam S.C.A. Novavax Inc Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$18.2 - $76.12 $1.66 Million - $6.93 Million	-91,000 Reduced 67.46%	43,894 $799,000
Q2 2022 Aug 03, 2022	BUY	$36.28 - $75.29 $4.68 Million - $9.72 Million	129,037 Added 2203.12%	134,894 $6.94 Million
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $4.68 Million - $9.59 Million	-67,078 Reduced 91.97%	5,857 $1.6 Million
Q4 2021 Feb 10, 2022	SELL	$134.56 - $217.97 $5.77 Million - $9.34 Million	-42,844 Reduced 37.0%	72,935 $10.4 Million
Q3 2021 Nov 09, 2021	SELL	$177.8 - $270.58 $1.34 Million - $2.04 Million	-7,544 Reduced 6.12%	115,779 $24 Million
Q2 2021 Jul 20, 2021	BUY	$121.0 - $257.67 $6.14 Million - $13.1 Million	50,774 Added 69.99%	123,323 $26.2 Million
Q4 2020 Jan 22, 2021	BUY	$78.74 - $139.5 $1.89 Million - $3.34 Million	23,974 Added 49.35%	72,549 $8.09 Million
Q3 2020 Oct 19, 2020	BUY	$79.44 - $178.51 $3.86 Million - $8.67 Million	48,575 New	48,575 $5.26 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.